Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
Loading...
Embargo End Date
ICR Authors
Authors
Gomes, F
Wong, M
Battisti, NML
Kordbacheh, T
Kiderlen, M
Greystoke, A
Luciani, A
Wong, M
Battisti, NML
Kordbacheh, T
Kiderlen, M
Greystoke, A
Luciani, A
Document Type
Journal Article
Date
2020-09-15
Date Accepted
2020-06-23
Abstract
Immunotherapy with checkpoint inhibitors against programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1) has been implemented in the treatment pathway of patients with non-small cell lung cancer (NSCLC) from locally advanced disease to the metastatic setting. This approach has resulted in improved survival and a more favourable toxicity profile when compared with chemotherapy. Following the successful introduction of single-agent immunotherapy, current clinical trials are focusing on combination treatments with chemotherapy or radiotherapy or even other immunotherapeutic agents. However, most of the data available from these trials are derived from, and therefore might be more applicable to younger and fitter patients rather than older and often frail lung cancer real-world patients. This article provides a detailed review of these immunotherapy agents with a focus on the data available regarding older NSCLC patients and makes recommendations to fill evidence gaps in this patient population.
Citation
British journal of cancer, 2020, 123 (6), pp. 874 - 884
Source Title
Publisher
SPRINGERNATURE
ISSN
0007-0920
eISSN
1532-1827
Collections
Research Team
Breast Cancer Clinical Research
Breast Cancer Clinical Research
Breast Cancer Clinical Research